Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

Clinical Performance of SARS-CoV-2 Molecular Testing

View ORCID ProfileDaniel A. Green, Jason Zucker, Lars F. Westblade, Susan Whittier, Hanna Rennert, Priya Velu, Arryn Craney, Melissa Cushing, Dakai Liu, Magdalena Sobieszczyk, Amelia K. Boehme, View ORCID ProfileJorge L. Sepulveda
doi: https://doi.org/10.1101/2020.05.06.20093575
Daniel A. Green
1Department of Pathology & Cell Biology, Columbia University Irving Medical Center, New York, NY
MD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Daniel A. Green
Jason Zucker
4Division of Infectious Diseases, Department of Internal Medicine, Columbia University Irving Medical Center, New York, NY
MD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Lars F. Westblade
2Department of Pathology and Laboratory Medicine, Weill Cornell Medicine, New York, NY
3Division of Infectious Diseases, Department of Internal Medicine, Weill Cornell Medicine, New York, NY
PhD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Susan Whittier
1Department of Pathology & Cell Biology, Columbia University Irving Medical Center, New York, NY
PhD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Hanna Rennert
2Department of Pathology and Laboratory Medicine, Weill Cornell Medicine, New York, NY
PhD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Priya Velu
2Department of Pathology and Laboratory Medicine, Weill Cornell Medicine, New York, NY
MD, PhD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Arryn Craney
2Department of Pathology and Laboratory Medicine, Weill Cornell Medicine, New York, NY
PhD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Melissa Cushing
2Department of Pathology and Laboratory Medicine, Weill Cornell Medicine, New York, NY
MD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Dakai Liu
5Department of Pathology and Clinical Laboratories, NewYork-Presbyterian Queens Hospital
PhD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Magdalena Sobieszczyk
4Division of Infectious Diseases, Department of Internal Medicine, Columbia University Irving Medical Center, New York, NY
MD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Amelia K. Boehme
6Department of Epidemiology and Neurology, Columbia University Irving Medical Center, New York, NY
PhD, MSPH
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jorge L. Sepulveda
1Department of Pathology & Cell Biology, Columbia University Irving Medical Center, New York, NY
MD, PhD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Jorge L. Sepulveda
  • For correspondence: jls2282{at}cumc.columbia.edu
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Supplementary material
  • Data/Code
  • Preview PDF
Loading

Abstract

Molecular testing for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the gold standard for diagnosis of coronavirus disease 2019 (COVID-19), but the test clinical performance is poorly understood. From 3/10/2020-5/1/2020 NewYork-Presbyterian laboratories performed 27,377 SARS-CoV-2 molecular assays from 22,338 patients. Repeat testing was performed in 3,432 patients, of which 2,413 had negative and 1,019 had positive first day results. Repeat-tested patients were more likely to be older, male, African-American or Hispanic, and to have severe disease. Among the patients with initially negative results, 18.6% became positive upon repeat-testing. Only 58.1% of any-time positive patients had a result of “detected” on the first test. The clinical sensitivity of COVID-19 molecular assays is estimated between 66.2 % and 95.6%, depending on the unknown number of false negative results in single-tested patients. Conversion to a negative result is unlikely to occur before 15 to 20 days after initial testing or 20-30 days after the onset of symptoms, with 50% conversion occurring at 28 days after initial testing. Forty-nine initially-positive patients converted to negative and then back to positive in subsequent days. Conversion from first day negative to positive results increased linearly with each day of testing, reaching 25% probability in 20 days. In summary, our study provides estimates of the clinical performance of SARS-CoV-2 molecular assays and suggests time frames for appropriate repeat testing, namely 15 to 20 days after a positive test and the same or next 2 days after a negative test in a patient with high suspicion for COVID-19.

Competing Interest Statement

The authors have declared no competing interest.

Funding Statement

No external funding was received

Author Declarations

All relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.

Yes

All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Data Availability

The anonymized data stripped of personal health identifiers sufficient for reproducing the results in this manuscript will be shared upon request and review by NYP, Cornell and Columbia Universities.

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.
Back to top
PreviousNext
Posted May 08, 2020.
Download PDF

Supplementary Material

Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
Clinical Performance of SARS-CoV-2 Molecular Testing
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Clinical Performance of SARS-CoV-2 Molecular Testing
Daniel A. Green, Jason Zucker, Lars F. Westblade, Susan Whittier, Hanna Rennert, Priya Velu, Arryn Craney, Melissa Cushing, Dakai Liu, Magdalena Sobieszczyk, Amelia K. Boehme, Jorge L. Sepulveda
medRxiv 2020.05.06.20093575; doi: https://doi.org/10.1101/2020.05.06.20093575
Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools
Clinical Performance of SARS-CoV-2 Molecular Testing
Daniel A. Green, Jason Zucker, Lars F. Westblade, Susan Whittier, Hanna Rennert, Priya Velu, Arryn Craney, Melissa Cushing, Dakai Liu, Magdalena Sobieszczyk, Amelia K. Boehme, Jorge L. Sepulveda
medRxiv 2020.05.06.20093575; doi: https://doi.org/10.1101/2020.05.06.20093575

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Infectious Diseases (except HIV/AIDS)
Subject Areas
All Articles
  • Addiction Medicine (430)
  • Allergy and Immunology (756)
  • Anesthesia (221)
  • Cardiovascular Medicine (3294)
  • Dentistry and Oral Medicine (364)
  • Dermatology (279)
  • Emergency Medicine (479)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (1171)
  • Epidemiology (13375)
  • Forensic Medicine (19)
  • Gastroenterology (899)
  • Genetic and Genomic Medicine (5153)
  • Geriatric Medicine (482)
  • Health Economics (783)
  • Health Informatics (3268)
  • Health Policy (1140)
  • Health Systems and Quality Improvement (1190)
  • Hematology (431)
  • HIV/AIDS (1017)
  • Infectious Diseases (except HIV/AIDS) (14627)
  • Intensive Care and Critical Care Medicine (913)
  • Medical Education (477)
  • Medical Ethics (127)
  • Nephrology (523)
  • Neurology (4925)
  • Nursing (262)
  • Nutrition (730)
  • Obstetrics and Gynecology (883)
  • Occupational and Environmental Health (795)
  • Oncology (2524)
  • Ophthalmology (724)
  • Orthopedics (281)
  • Otolaryngology (347)
  • Pain Medicine (323)
  • Palliative Medicine (90)
  • Pathology (543)
  • Pediatrics (1302)
  • Pharmacology and Therapeutics (550)
  • Primary Care Research (557)
  • Psychiatry and Clinical Psychology (4212)
  • Public and Global Health (7504)
  • Radiology and Imaging (1705)
  • Rehabilitation Medicine and Physical Therapy (1013)
  • Respiratory Medicine (980)
  • Rheumatology (480)
  • Sexual and Reproductive Health (497)
  • Sports Medicine (424)
  • Surgery (548)
  • Toxicology (72)
  • Transplantation (236)
  • Urology (205)